VALENCIA, Calif. and TAMPA, Fla., March 08, 2017 -- MannKind Corporation and Bella & Elle Media LLC announce MannKind’s sponsorship of “Reversed,” a production series aimed at educating the show’s participants and viewing audience about the effects of poorly managed diabetes and its impact on their lives. “Reversed” will air on Discovery Life Channel in the summer of 2017.
|
|||
“Reversed” was created by Celebrity Chef and Diabetes Advocate, Charles Mattocks. The award-winning producer and bestselling author will host “Reversed,” as it follows the lives of individuals affected by diabetes and their struggle to change their diet, exercise and mindset about the disease. “Reversed” will feature experts such as diabetes educators, endocrinologists, therapists, nutritionists, and trainers, as well as celebrity guests who are also living with diabetes, to help encourage the contestants.
Charles Mattocks, nephew of legendary Bob Marley, said, “My uncle made an impact on the world through music and my vision is to impact health. 'Reversed' is about changing the behavior of those with diabetes. I am excited that MannKind has joined 'Reversed' in our mission."
Michael Castagna, Chief Commercial Officer of MannKind Corporation, added, “MannKind is continually seeking platforms to increase awareness around the challenges, opportunities and success people living with diabetes encounter on a daily basis. Mr. Mattock’s educational platforms, which have been featured on CNN, Dr. Oz and The Today Show, showcase the strength and determination of people fighting to make their lives better as they fight diabetes. We are excited to be associated with Mr. Mattock’s continuing efforts to educate the public.”
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
ABOUT BELLA & ELLE MEDIA LLC
For more information visit www.reversedyourhealth.com and sign up for updates on the show and the other work being done to help educate and empower individuals affected by this disease. Questions about the movement that is REVERSED can be directed to Charles Mattocks at [email protected].
MannKind Contact: Rose Alinaya SVP, Finance 661-775-5300 [email protected] Bella & Elle Media LLC Contact: Charles Mattocks 201-755-5386 [email protected]


Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 



